
PATIENT ENGAGEMENT IN 2030

How can patient engagement contribute towards building a new ecosystem for drug development & therapy?

Patient engagement has become a key element in drug development during recent years and will only become more important as time goes on. At the same time, these processes are undergoing change towards a new ecosystem. By taking the lessons learned from the past, taking current initiatives and bright ideas for the future, patient engagement plays a crucial role in the future of drug development & therapy.





In Q2 2022 (exact date to be confirmed), admedicum Business for Patients will organize an event in collaboration with HollandBIO where patient representatives will set the scene and subsequently multiple stakeholder speakers will share perspectives towards solutions, improvements and opportunities for patient engagement in 2030. The different perspectives will be followed by an interactive and open 'parliamentary style' debate.

Practical info
Q2 2022 (exact date to
be confirmed)

14:00 doors open, 14:45 program, 17:30 drinks Muntgebouw, Leidseweg 9, Utrecht, the Netherlands

Sharing knowledge & networking Meet up with people in person!

All necessary and mandatory COVID-19 measures will be fully implemented with special attention for attendees falling in a higher-risk category.



PATIENT ENGAGEMENT IN 2030

How can patient engagement contribute towards building a new ecosystem for drug development & therapy?

Program

ogram	
14:00 - 14:45	Registration Coffee-tea / refreshments
14:45 - 14:50	Welcome Philipp von Gallwitz, Co-Founder admedicum Business for Patients
14:50 - 15:20	Keynote - Nicola Bedlington, former Secretary General European Patient' Forum How to achieve structured systematic ethical patient engagement by 2030. The role of patient engagement in the life cycle of medicines (e.g. PFDD, PARADIGM initiative, patient education).
15:20 - 16:00	Solutions / improvements / opportunities for patient engagement during the drug development phase and after market entry from different stakeholder perspectives (part 1)
15:20 - 15	:40 Regulatory perspective by Cécile Ollivier, OCM Director - Regulatory Science EU Critical Path Institute (C-Path)
15:40 - 16	:00 Patient community driven alliances by Ana Mingorance, Chief Development Officer (Loulou Foundation)
16:00 - 16:20	Break Coffee & tea / water
16:20 - 17:00	Solutions / improvements / opportunities for patient engagement during the drug development phase and after market entry from different stakeholder perspectives (part 2)
16:20 - 16	:40 Industry perspective drug development phase by Annamarie Dillon, Senior Director Patient Advocacy (Orchard Therapeutics)
16:40 - 17	:00 Industry perspective market access phase by Joep Rijnierse, Medical Director (Amgen Nederland)
17:00 - 17:30	Parliamentary debate Moderated by Roger Legtenberg, Senior Partner & Head of Benelux Region admedicum Business for Patients
17.30 - 18:30	Networking Drinks & dinner snacks

N.B.: Focus of complete event should be positive towards solutions and not looking back negatively.

Join us!

